Israel Cancer Immunotherapy Market to 2032
Overview
The Israel Cancer Immunotherapy Market is expected to reach a 175.11 USD Million by 2032 and is projected to grow at a CAGR of 7.21% from 2025 to 2032.
Revenue, 2024 (USD Million)
107.97
Forecast, 2032 (USD Million)
175.11
CAGR, 2024 - 2032
7.21%
Report Coverage
Israel
Israel Cancer Immunotherapy Market 2018-2032 USD Million
Israel Cancer Immunotherapy Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 107.97 USD Million
- Projected Market Size (2032): 175.11 USD Million
- CAGR (2025-2032): 7.21%
Key Findings of Israel Cancer Immunotherapy Market
- The Israel Cancer Immunotherapy Market was valued at 107.97 USD Million in 2024.
- The Israel Cancer Immunotherapy Market is likely to grow at a CAGR of 7.21% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Intravenous (IV) in Form Segment accounted for the largest share of the market with a revenue of 99.19 USD Million
- The fastest growing segment Breast Cancer in Application Segment grew Fastest with a CAGR of 9.72% during the forecast period from 2024 to 2032.
Israel Cancer Immunotherapy Market Scope
Israel Cancer Immunotherapy Market Segmentation & Scope
Application
- Head & Neck Cancer
- Others
- Colorectal Cancer
- Multiple Myeloma
- Prostate Cancer
- Ovarian Cancer
- Cervical Cancer
- Stomach Cancer
- Breast Cancer
- Melanoma
- Lung Cancer
End User
- Hospitals
- Oncology Clinics
- Homecare
- Others
Form
- Intravenous (IV)
- Intramuscular
- Oral
Distribution Channel
- Direct Tenders
- Retail Sales
- Pharmacies
Product
- Vaccines
- Cell Therapies
- Immunomodulators
- Oncolytic Virus
- Monoclonal Antibodies
- Checkpoint Inhibitors
Israel Cancer Immunotherapy Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 107.97 USD Million |
| Market Value in 2032 | 175.11 USD Million |
| CAGR (2025-2032) | 7.21% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Application,End User,Form,Distribution Channel,Product |
Regional Insights:
-
Leading Market (2024-2032): Israel, leading in terms of revenue 107.97 USD Million in 2024
- Key Country: Israel, leading in terms of revenue with value of 107.97 USD Million in 2024.
Segments and Scope
-
Israel Cancer Immunotherapy Market to 2032, By Application
- Lung Cancer is the largest segment in Israel Cancer Immunotherapy Market to 2032 with a revenue of 39.57 USD Million in the year 2024.
- Breast Cancer is the Fastest growing segment in Israel Cancer Immunotherapy Market to 2032 with a Growth rate of 8.70 % in forecast period 2025-2032.
-
Israel Cancer Immunotherapy Market to 2032, By End User
- Hospitals is the largest segment in Israel Cancer Immunotherapy Market to 2032 with a revenue of 77.75 USD Million in the year 2024.
- Hospitals is the Fastest growing segment in Israel Cancer Immunotherapy Market to 2032 with a Growth rate of 7.33 % in forecast period 2025-2032.
-
Israel Cancer Immunotherapy Market to 2032, By Form
- Intravenous (IV) is the largest segment in Israel Cancer Immunotherapy Market to 2032 with a revenue of 99.19 USD Million in the year 2024.
- Intravenous (IV) is the Fastest growing segment in Israel Cancer Immunotherapy Market to 2032 with a Growth rate of 7.28 % in forecast period 2025-2032.
-
Israel Cancer Immunotherapy Market to 2032, By Distribution Channel
- Direct Tenders is the largest segment in Israel Cancer Immunotherapy Market to 2032 with a revenue of 76.64 USD Million in the year 2024.
- Direct Tenders is the Fastest growing segment in Israel Cancer Immunotherapy Market to 2032 with a Growth rate of 7.63 % in forecast period 2025-2032.
-
Israel Cancer Immunotherapy Market to 2032, By Product
- Checkpoint Inhibitors is the largest segment in Israel Cancer Immunotherapy Market to 2032 with a revenue of 74.72 USD Million in the year 2024.
- Checkpoint Inhibitors is the Fastest growing segment in Israel Cancer Immunotherapy Market to 2032 with a Growth rate of 7.37 % in forecast period 2025-2032.
Israel Cancer Immunotherapy Market Company Share Analysis
| Company Name |
|
||
| Merck & Co., Inc. | |||
| Janssen Pharmaceuticals, Inc. | |||
| Bristol-Myers Squibb Company | |||
| AstraZeneca | |||
| Gilead Sciences, Inc. | |||
Israel Cancer Immunotherapy Market Geographical Sales Distribution, 2018-2032 USD Million
Israel Cancer Immunotherapy Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Israel Cancer Immunotherapy Market is segmented based on Segmentation Application,End User,Form,Distribution Channel,Product.
Israel Cancer Immunotherapy Market was valued at USD 107.97(Revenue in USD Million) in 2021.
Israel Cancer Immunotherapy Market is projected to grow at a CAGR of 7.21% during the forecast period of 2024 to 2032.
The Intravenous (IV) segment is expected to dominate the Israel Cancer Immunotherapy Market, holding a largest market share of 99.19 USD Million in 2024
Israel Cancer Immunotherapy Market Scope
Israel Cancer Immunotherapy Market Segmentation & Scope
Application
- Head & Neck Cancer
- Others
- Colorectal Cancer
- Multiple Myeloma
- Prostate Cancer
- Ovarian Cancer
- Cervical Cancer
- Stomach Cancer
- Breast Cancer
- Melanoma
- Lung Cancer
End User
- Hospitals
- Oncology Clinics
- Homecare
- Others
Form
- Intravenous (IV)
- Intramuscular
- Oral
Distribution Channel
- Direct Tenders
- Retail Sales
- Pharmacies
Product
- Vaccines
- Cell Therapies
- Immunomodulators
- Oncolytic Virus
- Monoclonal Antibodies
- Checkpoint Inhibitors
Frequently Asked Questions
The Israel Cancer Immunotherapy Market is segmented based on Segmentation Application,End User,Form,Distribution Channel,Product.
Israel Cancer Immunotherapy Market was valued at USD 107.97(Revenue in USD Million) in 2021.
Israel Cancer Immunotherapy Market is projected to grow at a CAGR of 7.21% during the forecast period of 2024 to 2032.
The estimated market value of the Israel Cancer Immunotherapy Market for final year is USD 175.11 (USD Million).
Israel Cancer Immunotherapy Market Company Profiling
Frequently Asked Questions
The Israel Cancer Immunotherapy Market is segmented based on Segmentation Application,End User,Form,Distribution Channel,Product.
Israel Cancer Immunotherapy Market was valued at USD 107.97(Revenue in USD Million) in 2021.
Israel Cancer Immunotherapy Market is projected to grow at a CAGR of 7.21% during the forecast period of 2024 to 2032.
The estimated market value of the Israel Cancer Immunotherapy Market for final year is USD 175.11 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.